WeSearch

STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

STAT Staff· ·1 min read · 0 reactions · 0 comments · 15 views
STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

Original article
STAT News · STAT Staff
Read full at STAT News →
Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from STAT News

STAT+: Legend Biotech emerged as a rare market winner
STAT News·7
STAT+: China competition, ‘destruction’ at FDA gives agency chance to restructure, Rick Pazdur says
STAT News·13
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
STAT News·17
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
STAT News·15
STAT+: Allogene CEO David Chang stepping down
STAT News·19
STAT+: Up and down the ladder: The latest comings and goings
STAT News·12